Runt-related transcription factor 1 mRNA (RUNX1 mRNA)

Runt-related transcription factor 1 (RUNX1) mRNA encodes a critical protein involved in the generation of hematopoietic stem cells and their subsequent differentiation into various blood lineages (UniProt P14921). As a member of the core-binding factor (CBF) family, the RUNX1 protein forms a heterodimer with CBF-beta to regulate the transcription of genes essential for normal blood cell development (NCBI Gene ID 861). Mutations, translocations, or dysregulated expression of RUNX1 mRNA are frequently associated with hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (PubMed PMID: 28334969). Specifically, the t(8;21) translocation creates a fusion mRNA (RUNX1-RUNX1T1) that acts as a dominant-negative inhibitor of wild-type RUNX1 function (PubMed PMID: 11588177). Targeting RUNX1 mRNA using antisense oligonucleotides or RNA interference (RNAi) represents a therapeutic strategy to modulate the expression of this transcription factor in cases where its overactivity or fusion products drive oncogenesis (PubMed PMID: 25665114). Experimental approaches have demonstrated that silencing the RUNX1-RUNX1T1 fusion transcript can induce apoptosis and differentiation in leukemia cells (PubMed PMID: 15150103). However, because RUNX1 is indispensable for normal hematopoiesis, therapeutic interventions must carefully balance the inhibition of malignant cells with the preservation of healthy blood cell production (PubMed PMID: 22517900).

Other names

AML1 mRNACBFA2 mRNAPEBP2aB mRNAAcute myeloid leukemia 1 mRNACore-binding factor subunit alpha-2 mRNA

RNA interference (RNAi) or antisense-mediated degradation of RUNX1 transcripts to modulate protein expression levels or silence oncogenic fusion transcripts.